ArticleAmerican journal of translational research2025
Clinical value of miR-216a-5p and miR-34a in early screening for cervical cancer.
Article in American journal of translational research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo investigate the clinical value of miR-216a-5p and miR-34a in early screening for cervical cancer (CC).
methods99 patients were selected and classified into a cervical cancer group, a precancerous lesion group, and a chronic cervicitis group, with 33 patients in each group. The miR-216a-5p and miR-34a levels in the morning urine samples of patients in the three groups were detected. Additionally, the urine samples of CC patients were analyzed and their cervical tissues examined to confirm the presence of Human Papilloma Virus (HPV) infection. The differences in the levels of miR-216a-5p and miR-34a in CC patients exhibiting varying clinical features and the clinical values of the two biomarkers in identifying CC were analyzed. Patients in the cervical cancer group were divided into a recurrence group and a non-recurrence group, after which their levels of miR-216a-5p and miR-34a were analyzed. These patients were subsequently divided into a high-expression group and a low-expression group with the aforementioned biomarker levels in the non-recurrence group as cutoff values. The progression-free survival was compared between the low- and high-expression groups.
resultsSensitivity and specificity of the urine sample test for HPV infection were 85.19% and 93.33%, respectively. Compared to chronic cervicitis group and precancerous lesion groups, or the non-recurrence group, the levels of miR-216a-5p and miR-34a in both the cervical cancer group and recurrence group were significantly lower (P < 0.05). CC patients with moderately to poorly differentiated tumor cells, an infiltration depth of the muscle layer > 1/2, lymph node metastasis, parametrial infiltration, or vascular invasion had significantly lower levels of miR-216a-5p and miR-34a than those without these risk factors (P < 0.05). The AUC for the application of the two biomarkers in diagnosing CC individually or in combination, or in forecasting recurrence, was greater than 0.8. Additionally, the cumulative progression-free survival was shorter in the low-expression group compared to the high-expression group.
conclusionUse of morning urine samples for testing HPV infection shows high sensitivity and specificity. Moreover, the miR-216a-5p and miR-34a levels were closely associated with the progression and recurrence of CC.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.